

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

013221

FEB | 1 1999

OFFICE OF THE ADMINISTRATOR

MEMORANDUM

SUBJECT:

Acetochlor - Tox. Studies with Metabolites, Submitted under MRID Nos. 446327-

03-04-05-06; and 446395-01

ID No. 066478-00002

P.C. Code: 121601 (003B)

Submission: S548078 D.P.Barcode: D249059

FROM:

Irving Mauer, Ph.D., Geneticist

Toxicology Branch 2

Health Effects Division (7509C)

THRU:

Stephen C. Dapson, Ph.D., Senior Branch Scientist

Toxicology Branch 2

Health Effects Division (7509C)

TO:

Jim Thompkins/Phil Errico, PM E5

Registration Division (7505C)

REGISTRANT:

Acetochlor Registration Partnership, c/o Zeneca Ag Products, Wilmington

DE

REQUEST:

Review and evaluate the following studies, submitted in response to the Agency's

letter of July 10, 1997 stating that the ESA (sulphonic acid) and oxanilic acid

degradation products may constitute residues of toxicological concern:

Study 1: Oxanilic Acid (R290130): Acute Oral Toxicity to the Rat, performed at (Zeneca's) Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (UK), Study No. AR6414/Report No. CTL/P/5644, dated 25 September 1997. MRID 44632703. Unpublished.

Study 2: Sulphonic Acid (R290131): Acute Oral Toxicity to the Rat, performed at (Zeneca's) Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (UK), Study No. AR 6415/Report No. CLT/P/5648, dated 17 November 1997. MRID 44632704. Unpublished.

Study 3: Oxanilic Acid (R290130): An Evaluation of Mutagenic Potential Using *S. typhimurium* and *E. coli*, performed at (Zeneca's) Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (UK), Study No. YV 3984/Report No. CTL/P/5542, dated 4 August 1997. MRID 44632705. Unpublished.

Study 4: Sulphonic Acid (R290131): An Evaluation of Mutagency Potential Using *S. typhimurium E. coli*, performed at (Zeneca's) Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (UK), Study No. YV 3985/Report No. CTL/P/5568, dated 4 August 1997. MRID 44632706. Unpublished.

Study 5: Acetochlor Soil Metabolites: Summary of Metabolism and Toxicology Studies, (Zeneca's) Laboratory Project ID BJK20, dated 14 August 1998. MRID 44639501. Unpublished.

TB CONCLUSIONS: These studies have been evaluated as follows (detailed reviews are attached).

			-
	Study/Type/Chemical (MRID)	Reported Results	Evaluation
1.	Acute oral/oxanilic acid (44632703)	LD50 (males/females) greater than 2000 mg/kg (the limit dose). Tox. Cat. III	Acceptable
2.	Acute oral/sulphonic acid (44632704)	LD50 (males/females) greater than 2000 mg/kg (the limit dose) Tox. Cat. III	Acceptable
3.	Bacterial reverse gene mutation/oxanilic acid (44632705)	Negative for induced gene mutation at doses up to the limit, 5000 ug/plate, with/without activation.	Acceptable
4.	Bacterial reverse gene mutation/sulphonic acid (44632706)	Negative for induced gene mutation at dosses up to the limit, 5000 ug/plate, with/without activation.	Acceptable
5.	Summary of Studies (44639501)	(Several metabolism and acute toxicology studies conducted with the oxanilic and sulfonic acid metabolites are summarized)	[Not assessed; summary only]

ACETOCHLOR

EPA Reviewer: Irving Mauer, Ph.D.

Toxicology Branch 2, Health Effects Division (7509C)
EPA Secondary Reviewer: Stephen C. Dapson, Ph.D.

Toxicology Branch 2, Health effects Division (7509C)

ACUTE ORAL STUDY (81-1)

013221

DATA EVALUATION RECORD

STUDY TYPE: Acute oral toxicity in the rat; OPPTS 870.1100 (81-1)

DP BARCODE: D249059

SUBMISSION CODE: S 548078

P.C. CODE: 121601

TOX. CHEM. NO.: 003B

TEST MATERIAL (PURITY): Oxanilic acid (metabolite of acetochlor, 97%)

SYNONYMS: R290130

CITATION: Lees, D. (1997). Oxanilic Acid (R290130): Acute Oral Toxicity to the Rat, performed at (Zeneca's) Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (UK), Study No. AR6414/Report No. CTL/P/5644, dated 25 September 1997. MRID 44632703. Unpublished.

SPONSOR: Acetochlor Registration Partnership, c/o Zeneca Ag Products, Wilmington (DE)

EXECUTIVE SUMMARY: In an acute oral toxicity study (MRID 44632703), a single group of five male and five female Alpk: AP_fSD (Wistar-derived) rats received a single oral dose of 2000 mg/kg test article. Animals were observed daily for 14 days for signs of clinical toxicity and body weight was recorded periodically throughout the study. At the end of the observation period, all animals were killed and examined macroscopically.

There were no deaths and none of the animals manifested or clinical macroscopically adverse findings; all showed overall weight gain during the study. Therefore, the acute median lethal dose (LD50) of oxanilic acid is estimated to be greater than 2000 mg/kg, the limit dose for this type of study. Tox. Cat. assigned is III.

This acute oral study is classified Acceptable-Guideline and satisfies the requirement for an acute oral study (81-1) in the rat.

COMPLIANCE: Signed and dated GLP, Quality Assurance, Data confidentiality, and flagging statements were provided.

I. MATERIALS AND METHODS

A. Materials:

1. <u>Test Material</u>: Oxanilic acid (R290130)

Description: White solid

Lot/Batch No.: OSW 01738-OIR

Purity: 97% a.i.

CAS No.: [Not provided]

Verification of concentration/homogeneity: Not provided

2. <u>Vehicle and/or positive control</u>:

Corn oil

Positive control: None.

3. <u>Test animals</u>: Species: Rat

Strain: Alpk:AP_fSD

Age and/or weight at dosing: 8-12 weeks/males: 288-329 g; females: 217-

244g.

Source: Rodent Breeding Unit, Alderley Park, Macclesfield, Cheshire

(UK)

Acclimation period: Five days Diet: R&M No.1 ad libitum
Water: Mains ad libitum
Environmental conditions:

Temperature, 22±30 degrees C

Humidity, 30-70%

Air changes, 15+ per hour

Photoperiod: 12 hours light/12 hours dark

B. <u>STUDY DESIGN AND METHODS</u>:

- 1. <u>In life dates</u>: start: 9 June/end: 24 June 1997
- 2. Animal assignment and treatment: Animals were assigned to the test groups noted in Table 1. Following an overnight fast, rats were given a single dose of 2000 mg/kg by gavage, then observed daily for 14 days, and weighed prior to fasting (day -1), immediately before dosing (day 1) and on days 8 and 15. Survivors were sacrificed and a necropsy was performed.

3. <u>Statistics</u>: The oral LD50 was not calculated since no deaths occurred at the limit dose, 2000 mg/kg.

Table 1. Doses, Mortality/Animals Treated					
Dose (mg/kg) Males Females Combined					
2000	0/5	0/5	0/10		

II. RESULTS AND DISCUSSION

- A. Mortality is given in Table 1, above (derived from MRID 44632703 Report, page 18, attached). The oral LD50 for males and females is greater than 2000 mg/kg (the limit dose for this type of study).
- B. <u>Clinical observations</u>: No adverse clinical abnormalities observed (MRID 44632703 Report Table 2, pages 19-23).
- C. <u>Body weight</u>: Overall body weight gain throughout study (MRID 44632703 report Table 3, page 24).
- D. <u>Necropsy</u>: No treatment-related macroscopic findings (MRID 44632703 Table 4, pages 25-34).
- E. <u>Deficiencies</u>: [None]

THE FOLLOWING ATTACHMENT IS NOT AVAILABLE ELECTRONICALLY -- SEE THE FILE COPY

ATTACHMENT

TABLE 1 - CUMULATIVE MORTALITY DATA

Dose level	Day Number	Number of Deaths				
(mg/kg)		Male	Female			
2000	- -	0	0			
	15 (total)	0/5	0/5			

ACUTE ORAL STUDY (81-1)

EPA Reviewer: Irving Mauer, Ph.D.

Toxicology Branch 2, Health Effects Division (7509C)

Secondary EPA Reviewer: Stephen C. Dapson, Ph.D.

Toxicology Branch 2, Health Effects Division (7509C)

013221

DATA EVALUATION RECORD

STUDY TYPE: Acute oral toxicity in the rat, OPPTS 870.1100 (81-1)

DP BARCODE: D249059

SUBMISSION CODE: S 548078

P.C. CODE: 121601

TOX. CHEM. NO.: 003B

TEST MATERIAL (PURITY): Sulphonic acid (ESA metabolite of acetochlor, 97%)

SYNONYMS: R290131

CITATION: Lees D. (1997) Sulphonic Acid (R290131): Acute Oral Toxicity to the Rat, performed at (Zeneca's) Central Toxicology Lab, Alderley Park, Macclesfield, Cheshire (UK), Study No. AR 6415/Report No. CTL/P/5648. MRID 44632704. Unpublished.

SPONSOR: Acetochlor Registration Partnership, c/o Zeneca Ag Products, Wilmington (DE)

EXECUTIVE SUMMARY: In an acute oral toxicity study (MRID 44632704), a single group of five male and five female Wistar-derived rats received a single oral dose of 2000 mg/kg test article, and were observed daily for 14 days, with periodic body weight measurement throughout the study. At termination, all animals were necropsied and subjected to a macroscopic examination post-mortem.

No animals died, and there were no treatment-related clinical signs, necropsy findings or significant changes in body weight. Tox. Cat. assigned is III.

This acute oral study is classified Acceptable-Guideline and satisfies the Guideline requirement for an acute oral study (81-1) in the rat.

COMPLIANCE: Signed and dated GLP, Quality Assurance, Data Confidentiality, and Flagging statements were provided.

I. MATERIALS AND METHODS

A. <u>MATERIALS</u>:

1. <u>Test Material</u>: Sulphonic acid (R290131)

Description: White solid

Lot/Batch No.: ASW 01741-01R, TSC 0452/03623

Purity: 97% a.i.

CAS No.: [Not provided]

Verification of concentration/homogeneity: Not provided.

2. <u>Vehicle and/or positive control</u>:

Deionized Water (DW) [No positive control.]

3. <u>Test animals</u>: Species: rat

Strain: Alpk:AP_tSD

Age and/or weight at dosing: 8-12 weeks; males 292-346g /females 202-236 g. Source: Rodent Breeding Unit, Alderley Park, Mecclesfield, Cheshire (UK)

Diet: R&M No. 1 ad libitum

Water: ad libitum

Environmental Conditions:

Temperature: 22±3 degrees C

Humidity: 30-70%

Air changes: 1.5+ per hour

Photoperiod: 12 hours light/12 hours dark

B. <u>STUDY DESIGN and METHODS</u>:

1. In life dates - start: 16 June/end: 10 July 1997

2. Animal assignment and treatment: Animals were assigned to the test groups noted in Table 1. Following an overnight fast, rats were given a single dose of 2000 mg/kg by gavage, then observed and weighed (periodically) for 14 days. Survivors were sacrificed and a necropsy was performed.

Dose (Mg/kg)	Males	Females	Combined
2000	0/5	0/5	0/10
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		

3. <u>Statistics</u>: The oral LD50 was not calculated since no deaths occurred at 2000 mg/kg, the limit dose (see below).

II. RESULTS AND DISCUSSION:

- A. Mortality is given in Table 1 (derived from MRID 44632704 Table 1, Report page 18, attached). The oral LD50 for males and females is greater than 2000 mg/kg.
- B. <u>Clinical observations</u> There were no signs of clinical toxicity (MRID 46632704 Table 2, Report pages 19-23).
- C. <u>Body weight</u> All animals gained body weight during the study. (MRID 44632704 Table 3, Report page 24).
- D. <u>Necropsy</u> There were no compound-related findings at the examination <u>postmortem</u>. (MRID 44632704, Table 4, Report pages 25-34).
- E. <u>Deficiencies</u> There were no deficiencies.

THE FOLLOWING ATTACHMENT IS NOT AVAILABLE ELECTRONICALLY -- SEE THE FILE COPY

ATTACHMENT

TABLE 1 - CUMULATIVE MORTALITY DATA

Dose level	Day Number	Number of Deaths				
(mg/kg)		Male	Female			
2000	-	0	0			
	15 (total)	0/5	0/5			

ACETOCHLOR

BACTERIA/MAMMALIAN ACTIVATION; GENE MUTATION (84-2)

EPA Reviewer: Irving Mauer, Ph.D.

Toxicology Branch 2, Health Effects Division (7509C)

EPA Secondary Reviewer:

Toxicology Branch 2, Health Effects Division (7509C

Date: 10-28-98

Date: 11/13/98

013221

DATA EVALUATION RECORD

STUDY TYPE:

Bacterial systems (Salmonella, E. coli)/mammalian activation gene

mutation assay; OPPTS 870.5100 (84-2)

DP BARCODE: D 249059

SUBMISSION CODE: S 548078

P.C. CODE: 121601

TOX. CHEM. NO.: 003B

TEST MATERIAL (PURITY): Oxanilic acid (R290130, acetochlor metabolite, 97%)

SYNONYMS: [None]

SPONSOR: Acetochlor Registration Partnership, c/o Zeneca Ag Products, Wilmington (DE)

<u>CITATION</u>: Callander, R.D. (1997) Oxanilic Acid (R290130): An Evaluation of Mutagenic Potential Using S. typhimurium and E. coli, performed at (Zeneca's) Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (UK), Study No. YV 3984/Report No. CTL/P/5542, dated 4 August 1997. MRID 44632705. Unpublished.

EXECUTIVE SUMMARY: In a reverse gene mutation assay in bacteria (MRID 44632705), four mutant (his') strains of Salmonella typhimurium (TA1535, TA1537, TA98 and two mutant (try') strains of Escherichia coli (WP2P and WP2P uvrA) were exposed in two separate trials to the oxanilic acid metabolite of acetochlor (97% a.i.) in the presence and absence of a rat liver-derived metabolic activation system (S9-Mix). Solvent controls and strain-specific mutagens were included in each trial.

The test material was tested up to 5000 ug /plate (the limit concentration) without the induction of any significant reproducible increases in the frequency of revertant colonies (his+,try+) under either condition of activation (\pm S9)in either trial. Positive controls gave the expected mutagenic responses. Hence, oxanilic acid is non-mutagenic in this bacterial assay.

This study is classified as Acceptable-Guideline and satisfies the requirement for FIFRA Test Guideline 84-2 for *in vitro* mutagenicity (bacterial reverse gene mutation) data.

<u>COMPLIANCE</u>: Signed and dated GLP, Quality Assurance, Data Confidentiality, and Flagging statements were provided.

I. MATERIALS AND METHODS

1. <u>Test Material</u>: Oxanilic acid (R290130)

Description: White solid.

Lot/Batch No. ASW01738-01R

Purity: 97% a.i.

Stability of compound: Not performed, but Certificate of Analysis (dated

March 7, 1997) provided. CAS No.: [Not provided]

Solvent used: Sterile deionized water

2. <u>Control Materials:</u>

Negative: [Not included]

Solvent/final concentration: 100 uL/plate

Positive: Non-activation:

Sodium azide: 0.5, 1.0, 2.0 ug/plate for TA100, TA1535

Daunomycin HCl: 0.2, 0.5, 1.0 ug/plate for TA98

ICR-191 (acridine mutagen): 0.5, 1.0, 2.0 ug/plate for TA1537

Other (list):

Mitomycin-C, 0.2, 0.5, 1.0 ug/plate for WP2P

EENG: 0.2, 0.5, 1.0: 0.2, 0.5, 1.0 ug/plate for WP2P uvrA

Activation:

2-Aminoanthracene (2-anthramine)

0.2, 0.5, 1.0 ug/plate for TA98, TA100,

0.5, 1.0, 2.0 ug/plate for TA1535, TA1537

5, 10, 20 ug/plate for WP2P

1, 2, 5 ug/plate for WP2P uvrA

3. <u>Activation</u>: S9 derived from male Sprague-Dawley rats.

	Aroclor 1254	x	induced	х	rat	liver
х	phenobarbital/ naphthaflavone		non-induced		mouse	lung
	none				hamster	other
	other					other

Describe S9 mix composition:

S9 fraction: 3 mL

Sucrose - Tris-EDTA buffer: 7 mL

Co-factor solution (Na, HPO₄, KCl, G-6-P, NADP, MgCl₂): 20 mL

4. <u>Test organisms</u>: S. typhimurium strains:

	TA97	x	TA98	х	TA100	TA102	TA104
x	TA1535	x	TA1537		TA1538		

List any others: E. coli strains: WP2P and WP2P uvrA.

Properly maintained: Yes.

Checked for appropriate genetic markers (rfa mutation, R factor)? Yes.

5. <u>Test compound concentrations used</u>

Non-activated conditions: 100, 200, 500, 1000, 2500, 5000 *ug*/plate. Activated conditions: 100, 200, 500, 1000, 2500, 5000 *ug*/plate.

B. TEST PERFORMANCE:

1. <u>Type of Salmonella assay</u>:

<u>X</u>	standard plate test (initial trial)
<u>X</u>	pre-incubation (60 minutes in second trial)
	"Prival" modification
	Spot test
	other (describe)

2. <u>Protocol</u>: Cultures of each strain were exposed to the above range of concentrations of test article, (three plates per concentration), or to 100 *ul*/plate solvent (5 plates), or in duplicate to above concentrations of reference mutagens, and incubated at 37 degrees C for three days. Revertant colonies were counted (by Automatic Colony Counter) and compared to solvent control values.

II. REPORTED RESULTS

Mutagenicity assay: (only) None of the cultures in either assay showed significant, reproducible (greater than twofold) increases over solvent controls in number of revertant colonies (Report Tables 1-4, pp. 21-24, attached). Therefore the investigator concluded that oxanilic acid was negative for induced mutagenicity in these bacterial strains under the conditions of this assay.

III. REVIEWER'S DISCUSSION/CONCLUSIONS:

- A. We agree with the author that under the conditions of these assays, oxanilic acid is non-mutagenic in the strains of *Salmonella* and *E. coli* tested.
- B. <u>STUDY DEFICIENCIES</u>: There are no deficiencies that would compromise the conclusions or assessment of this study.

Pag Pag	e is not included in this copy. es 8 through 22 are not included.
The	material not included contains the following type o
	Identity of product inert ingredients.
	Identity of product impurities.
	Description of the product manufacturing process.
	Description of quality control procedures.
	Identity of the source of product ingredients.
	Sales or other commercial/financial information.
	A draft product label.
	The product confidential statement of formula.
	Information about a pending registration action.
<u> </u>	FIFRA registration data.
	The document is a duplicate of page(s)
	The document is not responsive to the request.
	4
he j	information not included is generally considered confidentia oduct registrants. If you have any questions, please contact individual who prepared the response to your register.

-

ACETOCHLOR

BACTERIA/MAMMALIAN ACTIVATION; GENE MUTATION (84-2)

EPA Reviewer: Irving Mauer, Ph.D.

Toxicology Branch 2, Health Effects Division (1509C

EPA Secondary Reviewer:

Toxicology Branch 2, Health Effects Division (7509C

DATA EVALUATION RECORD

STUDY TYPE:

Bacterial systems, (Salmonella/E. coli)/mammalian activation gene

mutation assay; OPPTS 870.5100 (84-2)

DP BARCODE: D249059

SUBMISSION CODE:

S548078

P. C. CODE: 121601

TOX. CHEM. NO.: 003B

TEST MATERIAL (PURITY): Sulphonic acid (R290131, acetochlor metabolite, 97%)

SYNONYMS: [None]

CITATION: Callander, R.D. (1997) Sulphonic Acid (R290131): An Evaluation of Mutagenic Potential Using S. typhimurium and E. coli, performed at (Zeneca's) Genetic Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire (U.K.), Study No. YV3985/Report No. CTL/P/5568, dated 4 August 1997. MRID 44632706. Unpublished.

SPONSOR: Acetochlor Registration Partnership, c/o Zeneca Ag Products, Wilmington (DE)

EXECUTIVE SUMMARY: In a reverse gene mutation assay in bacteria (MRID 4432706), four mutant (his-) strains of Salmonella typhimurium (TA1535, TA1537, TA98 and TA100) and two mutant (try) strains of Escherichia coli (WP2P and WP2P uvrA) were exposed in two separate trials to the sulphonic acid metbolite of acetochlor (97% a.i.), in the presence and absence of a rat liver-derived metabolic system (S9-Mix). Solvent controls and strain-specific mutagens were included in each trial.

The test material was tested up to 5000 ug/plate (the limit concentration), without the induction of any significant, reproducible increase in the frequency of revertant colonies (his⁺, try⁺) under either condition of activation (±S9) in either trial. Positive controls responded with the expected increase in revertants. Hence sulphonic acid is considered non-mutagenic in this bacterial assay.

This study is classified as Acceptable-Guideline and satisfies the requirement for FIFRA Test Guideline 84-2 for in vitro mutagenicity (bacterial reverse gene mutation) data.

COMPLIANCE: Signed and dated GLP, Quality Assurance, Data confidentiality, and Flagging statements were provided.

I. MATERIALS AND METHODS

A. <u>MATERIALS</u>:

1. <u>Test Material</u>: Sulphonic acid (R290131)

Description: White solid

Lot/Batch No. ASW 01741-01R

Purity: 97% a.i.

Stability of compound: Not performed, but Certificate of Analysis (dated

March 3, 1977) provided. CAS. No.: [Not provided]

Solvent used: sterile deionized water

2. <u>Control Materials</u>:

Negative: [Not included]

Solvent/final concentration: 100 uL/plate

Positive:

Non-activation:

Sodium azide: 0.5, 1.0, 2.0 ug/plate for TA100, TA1535

Daunomycin HCl: 0.2, 0.5, 1.0 ug/plate for TA98 1CR191 (acridine mutagen): 0.5, 1.0, 2.0 ug/plate for

TA1537 Other (list):

Mitomycin C: 0.2, 0.5, 1.0 ug/plate for WP2P EENG: 0.2, 0.5, 1.0 ug/plate for WP2P uvrA

Activation:

2-Aminoanthracene (2-anthramine):

0.2, 0.5, 1.0 ug/plate for TA98, TA100

0.5, 1.0, 2.4 ug/plate for Ta 1535, TA1537

5, 10, 20 ug/plate for WP2P

1, 2, 5 ug/plate for WP2P uvrA

3. <u>Activation</u>: S9 derived from male Sprague-Dawley rats.

	Aroclor 1254	х	induced	х	rat	x	liver
х	phenobarbital/ naphthalflavone		non-induced		mouse		lung
	none				hamster		other
	other						other

,1

Describe S9 mix composition:

S9 fraction: 3mL

Sucrose-Tris-EDTA buffer: 7 mL

Cofactor solution: (Na₂HPO₄, KCl, G-6-P, NADP, MgCl₂): 20 mL

4. <u>Test compound concentrations used:</u>

Non-activated conditions: 100, 200, 500, 1000, 2500, 5000 ug/plate Activated conditions: 100, 200, 500, 1000, 2500, 5000 ug/plate

B. TEST PERFORMANCE

1. Type of Salmonella assay:

X	standard plate test (initial trial)
X	pre-incubation (60 minutes, i.e., second trial)
	"Prival" modification
	_ spot test
	_ other (describe)

2. Protocol: Cultures of each strain were exposed to the above range of test article concentrations (three plates per concentration), or to 100 ul/plate solvent (5 plates), or in duplicate to the above concentrations of reference mutagens, and incubated at 37 degrees C for three days. Revertant colonies were counted (by Automatic Colony Counter) and compared to solvent control values.

II. REPORTED RESULTS

Mutagenicity assay (only): Except for slight but significant increases in TA1537 test cultures in the first plate incorporation assay under S9 activation, none of the other test cultures in either assay showed significant reproducible increases (greater than two-fold) over solvent controls in the number of revertants (Report Tables 1-4, pp. 21-24). The increases noted in TA1537 were not reproducible in the pre-incubation trial (Table 2) nor in the second plate incorporation experiment (Table 4), hence were not considered biologically relevant. The investigator concluded that sulphonic acid was negative for induced mutagenicity in these bacterial strains under the conditions of this assay.

III. REVIEWER'S DISCUSSION/CONCLUSIONS:

A. We agree with the investigator that sulphonic acid was not mutagenic in the strains of *Salmonella* and *E. coli* tested under the conditions of this assay.

B. <u>STUDY DEFICIENCIES:</u>

There were no deficiencies that would compromise the conclusions or assessment of this study.

Pag	e is not included in this copy. es 27 through 32 are not included.
	are not included.
he nfo	material not included contains the following type of
	_ Identity of product inert ingredients.
	Identity of product impurities.
	Description of the product manufacturing process.
	Description of quality control procedures.
	Identity of the source of product ingredients.
· ·	Sales or other commercial/financial information.
	A draft product label.
	The product confidential statement of formula.
	Information about a pending registration action.
_	FIFRA registration data.
<u> </u>	The document is a duplicate of page(s)
· ,	The document is not responsive to the request.
	
	information not included is generally considered confidential coduct registrants. If you have any questions, please contact individual who prepared the response to your reguest.